Assessment of Serum Interferon Gamma-Induced Protein 10 in Chronic Hepatitis B Patients
Abstract
Objective: This study assessed the serum levels of IP-10 alongside standard liver function parameters, including Alanine Transaminase (ALT), Aspartate Transaminase (AST), Total Serum Bilirubin (TSB), Albumin, and Prothrombin Time (PT), in patients with Chronic hepatitis B (CHB). Additionally, the study sought to analyze the correlations among these variables.
Material and Methods: A case-control study was conducted with a total of 80 participants, comprising 40 patients diagnosed with CHB and 40 healthy controls. Serum IP-10 levels were quantified utilizing a commercial Enzyme-Linked Immunosorbent Assay (ELISA) kit. The standard automated methods were employed to conduct liver function tests.
Results: Patients with CHB demonstrated significantly elevated levels of IP-10 (221.6±68 vs. 111.2±32.1 pg/mL; p-value<0.001), ALT, AST, and TSB, while showing significantly reduced albumin levels compared to the control group (p-value<0.001). IP-10 exhibited remarkable diagnostic performance, achieving an Area Under the Curve of 0.96, with sensitivity at 92.5%, and specificity at 87.0% when using a cut-off of >156.2 pg/mL. A significant negative correlation was observed between IP-10 and albumin (r=-0.41, p-value<0.01), alongside a positive correlation with TSB (r=0.32, p-value<0.05).
Conclusion: Serum IP-10 is a highly sensitive and specific biomarker for CHB, demonstrating a significant correlation with the markers of liver dysfunction and synthetic function. Its strong inverse relationship with albumin suggests its potential role in indicating impaired hepatic synthesis, supporting its utility in the clinical evaluation and treatment of CHB.
Keywords
Full Text:
PDFReferences
Seto WK, Lo YR, Pawlotsky JM, Yuen MF. Chronic hepatitis B virus infection. Lancet 2018;392:2313–24.
Hsu YC, Huang DQ, Nguyen MH. Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol 2023;20:524–37. doi: 10.1038/s41575-023-00760-9.
Salman AH, Ali ZA, Selman NA. Hepcidin Level in Sera of Patients with Chronic Hepatitis B Virus in Babylon Province. Med J Babylon 2023;20.
Iannacone M, Guidotti LG. Immunobiology and pathogenesis of Hepatitis B Virus infection. Nat Rev Immunol 2022;22:19–32.
Lazarevic I, Tomasiewicz K. Editorial: Chronic Hepatitis B management: current status and future directions. Front Med 2025;12.
Hudu SA, Shinkafi SH, Jimoh AO. A critical review of diagnostic and prognostic markers of chronic Hepatitis B infection. Med Rev 2024;4:225–34. doi: 10.1515/mr-2024-0022.
Tamber SS, Bansal P, Sharma S, Singh RB, Sharma R. Biomarkers of liver diseases. Mol Biol Rep 2023;50:7815–23. doi: 10.1007/s11033-023-08666-0.
Kalas MA, Chavez L, Leon M, Taweesedt PT, Surani S. Abnormal liver enzymes: A review for clinicians. World J Hepatol 2021;13:1688.
Newsome PN, Cramb R, Davison SM, Dillon JF, Foulerton M, Godfrey EM, et al. Guidelines on the management of abnormal liver blood tests. Gut 2018;67:6-19.
Agrawal S, Dhiman RK, Limdi JK. Evaluation of abnormal liver function tests. Postgrad Med 2016;92:223–34.
Youssef EM, Wu GY. Subnormal Serum Liver Enzyme Levels: A Review of Pathophysiology and Clinical Significance. J Clin Transl Hepatol 2024;12:428–35.
Liu M, Guo S, Hibbert JM, Jain V, Singh N, Wilson NO, et al. CXCL10/IP-10 in infectious diseases pathogenesis and potential therapeutic implications. Cytokine Growth Factor Rev 2011;22:121–30.
Willemse SB, Reesink HW, Ladee K, Karlas J, Gelderblom HC, Molenkamp R, et al. IP-10 in chronic hepatitis C patients treated with high-dose interferon. Neth J Med 2014;72:407–15.
Singh KP, Zerbato JM, Zhao W, Braat S, Deleage C, Tennakoon GS, et al. Intrahepatic CXCL10 is strongly associated with liver fibrosis in HIV-Hepatitis B co-infection. PLoS Pathog 2020;16:e1008744.
Tutku Kaçar Şahin MTKŞ, Burak Bereketoğlu MBB, Dogan HD, Kose MK, Kuscu FK, Kurtaran BK, et al. Effect of Promoter Region Polymorphisms in the IP-10 Gene on HBsAg Loss in Chronic Hepatitis B Patients. Hepat Mon 25:e160428.
Boyd A, Duchesne L, Lacombe K. Research gaps in viral hepatitis. J Int AIDS Soc 2018;21(Suppl 2):e25054.
Fabiani S. Hepatitis B virus infection and interferon-inducible protein-10. Clin Ter 2015;166:e188-96.
Wiegand SB, Beggel B, Wranke A, Aliabadi E, Jaroszewicz J, Xu CJ, et al. Soluble immune markers in the different phases of chronic hepatitis B virus infection. Sci Rep 2019;9:14118.
Zhao K, Yang T, Sun M, Zhang W, An Y, Chen G, et al. IP-10 Expression in Patients with Chronic HBV Infection and Its Ability to Predict the Decrease in HBsAg Levels after Treatment with Entecavir. Mol Cells 2017;40:418–25.
Sevgi DY, Bayraktar B, Gündüz A, Özgüven BY, Togay A, Bulut E, et al. Serum soluble urokinase-type plasminogen activator receptor and interferon-γ-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B. Wien Klin Wochenschr 2016;128:28–33.
Tawfeek RA, Hassan EAS, Badary MS, Mokhtar M, Ahmed EH. IFN-γ and IP-10 levels in HBV infected patients. Sphinx J Pharm Med Sci 2024;7:1–8.
Khlaiphuengsin A, Chuaypen N, Hirankarn N, Avihingsanon A, Crane M, Lewin SR, et al. Circulating BAFF and CXCL10 levels predict response to pegylated interferon in patients with HBeAg-positive chronic Hepatitis B. Asian Pacific J allergy Immunol 2021;39:129–35.
Yu X, Chen Y, Cui L, Yang K, Wang X, Lei L, et al. CXCL8, CXCL9, CXCL10, and CXCL11 as biomarkers of liver injury caused by chronic Hepatitis B. Front Microbiol 2022;13:1052917.
Su Z, Chen J, Zhang J, An Y, Liao Y, Wu X, et al. Circulating IL-1β, IL-17, and IP-10 as Potential Predictors of Hepatitis B Virus Infection Prognosis. J Immunol Res 2022;2022:5202898.
Wang Y, Yu W, Shen C, Wang W, Zhang L, Liu F, et al. Predictive Value of Serum IFN-γ inducible Protein-10 and IFN-γ/IL-4 Ratio for Liver Fibrosis Progression in CHB Patients. Sci Rep 2017;7:40404.
Gong LL, Zhao BB, Fan WF, Gong LY, Chen CF, Liu JJ, et al. Correlations of IFN-γ-inducible protein-10 with the risk of chronic hepatitis B and the efficacy of interferon therapy in Asians. Int J Clin Exp Pathol 2015;8:8367–75.
Zhang T, Ye B, Shen J. Prognostic value of albumin-related ratios in HBV-associated decompensated cirrhosis. J Clin Lab Anal 2022;36:e24338. doi: 10.1002/jcla.24338.
Carvalho JR, Machado MV. New Insights About Albumin and Liver Disease. Ann Hepatol 2018;17:547–60.
Jeng LB, Li TC, Hsu SC, Chan WL, Teng CF. Association of Low Serum Albumin Level with Higher Hepatocellular Carcinoma Recurrence in Patients with Hepatitis B Virus Pre-S2 Mutant after Curative Surgical Resection. J Clin Med 2021;10.
Refbacks
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.